The 20th R&D Meeting
March 3, 2023
Sysmex Corporation
Index
- Opening Presentation
- R&D Initiatives under the Mid-Term Management Plan
3 Creation of Testing Value in Key Domains in MTP
4 Initiatives for Diagnosis of the Central Nervous System Disease
Hisashi Ietsugu
Chairman and CEO
Kaoru Asano
Member of the Managing Board and
Senior Executive Officer
Senior Managing Director, CTO
Tatsuya Ohashi
Executive Vice President, Reagent Engineering Division
Tomokazu Yoshida
Member of the Managing Board
and Senior Executive Officer
Managing Director
Glossary
■The information contained in these materials is based on current judgements and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments in Japan and overseas may cause plans to change.
■These materials contain information about products, service and support (including those under development). This information
is not intended for advertising or promotional purposes. | 2 |
1 | Opening Presentation |
Hisashi Ietsugu
Chairman and CEO
3
Sysmex's Corporate Philosophy and the Source of Value Creation
Long-Term
Management
Goals
(2025)
Mid-Term
Management Plan
(through March 2024)
Long-Term Vision
Unique & Advanced Healthcare Testing Company
Positioning Targets
- Creating innovative diagnostic value as a global top-five company in IVD
- A leading company in personalized diagnostics for optimizing medical treatment
- A solution provider contributing to the advancement of primary care diagnostics
- An attractive company providing value and instilling confidence
- One Sysmex carrying out high-speed management
Source of value creation
Technology platforms
Cell measurement
Protein measurement
Gene measurement
Provision of products, services and quality
Instruments | Quality | ||||
Specialized | |||||
reagents | control | ||||
IT / software |
4
Changes in the Operating Environment and Initiatives over the Past 20 Years
Technology Healthcare
2000s | 2010s | 2020s | |||||||
Introduction of molecularly | Growing healthcare disparities | COVID-19 Pandemic | |||||||
targeted therapeutic drugs | among countries and regions due | Adoption of online medicine | |||||||
From treatment to prevention | to increasingly sophisticated testing | Optimization of medical | |||||||
(lifestyle diseases) | Further increases in medical | expenses | |||||||
expenses | |||||||||
Sequencing of the human genome | Rise of next-generation sequencers | Realization of personalized | |||||||
Rise of gene detection technology | Leap forward in high-speed | diagnostics | |||||||
Electronic medical charges and | communication technology | Implementation of liquid biopsy | |||||||
other use of ITC in healthcare | Advances in automation technology | Implementation of remote and | |||||||
virtual technologies | |||||||||
Sysmex
- R&D expenses: Approx. ¥4.0 billion
(FY2001 Results)
- Opening of Central Research Laboratories
- Opening of Technopark
- Liquid biopsy initiatives
- Expansion of unique testing
(OSNATM, hepatic fibrosis markers, etc.)
- Reinforcement of IT products
- Strengthening of global development structure
- R&D expenses: Approx. ¥33.5 billion,
( FY2022 Forecast)
- Global rollout of the XRTM-Series
- Advances in unique tests
(testing for Alzheimer's disease, etc.)
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sysmex Corporation published this content on 03 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2023 00:08:09 UTC.